Latest Breaking News On - Interim analysis targeted - Page 1 : comparemela.com

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023.

New jerseyUnited statesState of new jerseyCarl spanaFosun pharmaJersey economic development authorityPalatin technologies incDilutive funding through nj economic development programPrnewswire palatin technologies incSecurities exchangeJersey technology business tax certificate transfer programDry eye disease ongoingResults currently expected mid calendarUlcerative colitis commencedInterim analysis targetedFirst half calendar year